GlassScriptPhysician profile
Ibrahim Bshara
NPI 1740256445
$2,808.32
in general payments reported to CMS, 2019-2025
35 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $526 · 2021: $147 · 2022: $296 · 2023: $399 · 2024: $406 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,215.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $288.31 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Glaxosmithkline, LLC. | $203.59 | 2019-2024 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $198.86 | 2020-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $177.75 | 2019-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $173.61 | 2019-2025 | Spravato |
| Novo Nordisk INC | $148.88 | 2019-2025 | Ozempic, Rybelsus |
| Allergan, INC. | $148.85 | 2020 | |
| Abbott Laboratories | $148.14 | 2022-2024 | Freestyle Libre 3 |
| Abbvie INC. | $147.89 | 2021-2025 | Vraylar, Linzess, Viberzi |
| Merck Sharp & Dohme LLC | $132.30 | 2021-2023 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $119.87 | 2022-2024 | |
| Dexcom, INC. | $102.47 | 2023-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $97.77 | 2019-2023 | |
| Alnylam Pharmaceuticals INC. | $94.90 | 2025 | Onpattro |
| Novartis Pharmaceuticals Corporation | $92.90 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $63.33 | 2019 | |
| Astellas Pharma US INC | $57.09 | 2019-2024 | Veozah |
| Scilex Pharmaceuticals INC. | $47.30 | 2019 | |
| Xeris Pharmaceuticals, INC. | $34.80 | 2023-2024 | Gvoke Hypopen |
| Avanir Pharmaceuticals, INC. | $34.29 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.10 | 2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.78 | 2019 | |
| Amarin Pharma, INC. | $24.62 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $22.71 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $22.65 | 2020 | |
| Exact Sciences Corporation | $22.22 | 2025 | Cologuard Collection Kit |
| Ultragenyx Pharmaceutical INC. | $21.58 | 2020 | |
| Mission Pharmacal Company | $19.38 | 2019 | |
| Lundbeck LLC | $18.24 | 2024 | Rexulti |
| Scpharmaceuticals INC. | $16.45 | 2025 | |
| Ge Healthcare | $14.66 | 2021 | |
| Ucb, INC. | $14.35 | 2023 | Briviact |
| Janssen Biotech, INC. | $14.28 | 2019 | |
| Philips North America LLC | $12.97 | 2023 | |
| Nestle Healthcare Nutrition INC. | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibrahim Bshara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.